| Mrs Carol Jeanette Fairchild, ARNP | |
|
2020 Commerce Dr, Melbourne, FL 32904-2335 | |
| (321) 952-6000 | |
| (321) 637-3648 |
| Full Name | Mrs Carol Jeanette Fairchild |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 42 Years |
| Location | 2020 Commerce Dr, Melbourne, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972565547 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | ARNP2992062 (Florida) | Secondary |
| 101YM0800X | Counselor - Mental Health | ARNP2992062 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Circles Of Care Inc | 8729069380 | 22 |
News Archive
The causes of 40 percent of all cases of certain medulloblastoma - dangerous brain tumors affecting children - are hereditary.
The COVID-19 pandemic has caused rapid adoption, integration and development of artificial intelligence and machine learning into the healthcare industry.
For assessing severe trauma, single-pass whole-body computed tomography (CT) can prove but not definitively exclude the presence of injuries and should be performed later than 30 minutes after admission to an emergency department for optimal results, according to a study in CMAJ.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it ranked #23 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growing during the period from 2005-2009. Spectrum Pharmaceuticals grew 6,490% during this period.
› Verified 2 days ago
| Entity Name | Circles Of Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215345954 PECOS PAC ID: 8729069380 Enrollment ID: O20040528000379 |
News Archive
The causes of 40 percent of all cases of certain medulloblastoma - dangerous brain tumors affecting children - are hereditary.
The COVID-19 pandemic has caused rapid adoption, integration and development of artificial intelligence and machine learning into the healthcare industry.
For assessing severe trauma, single-pass whole-body computed tomography (CT) can prove but not definitively exclude the presence of injuries and should be performed later than 30 minutes after admission to an emergency department for optimal results, according to a study in CMAJ.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it ranked #23 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growing during the period from 2005-2009. Spectrum Pharmaceuticals grew 6,490% during this period.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Carol Jeanette Fairchild, ARNP 400 East Sheridan Rd, Melbourne, FL 32901-3122 Ph: (321) 722-5200 | Mrs Carol Jeanette Fairchild, ARNP 2020 Commerce Dr, Melbourne, FL 32904-2335 Ph: (321) 952-6000 |
News Archive
The causes of 40 percent of all cases of certain medulloblastoma - dangerous brain tumors affecting children - are hereditary.
The COVID-19 pandemic has caused rapid adoption, integration and development of artificial intelligence and machine learning into the healthcare industry.
For assessing severe trauma, single-pass whole-body computed tomography (CT) can prove but not definitively exclude the presence of injuries and should be performed later than 30 minutes after admission to an emergency department for optimal results, according to a study in CMAJ.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it ranked #23 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growing during the period from 2005-2009. Spectrum Pharmaceuticals grew 6,490% during this period.
› Verified 2 days ago